Form 4: Evoke Pharma Director Cam L. Garner Acquires Stock Options
SEC Filing
Director Cam L. Garner of Evoke Pharma Inc. reports the acquisition of stock options on January 28, 2025.
Summary
- Cam L. Garner, a director of Evoke Pharma Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on January 28, 2025.
- Garner acquired stock options (Right to Buy) for 8,750 shares of common stock at an exercise price of $4.45.
- The options vest in three equal installments annually, beginning one year after the vesting commencement date, and will be fully vested on the third anniversary, contingent upon continued service to the company.
- The expiration date for these options is January 27, 2035.
- Following the reported transaction, Garner directly owns 8,750 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of stock options by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/28/2025 | Date of transaction: Acquisition of stock options. |
| 01/29/2025 | Date of signature on the Form 4 filing. |
| 01/27/2035 | Expiration date of the acquired stock options. |
Keywords
Form 4, Evoke Pharma, Stock Options, Beneficial Ownership, Director, Garner, EVOK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.